Home page > News and press release
 

Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Authorize the processing of personal data
ARCHIVE NEWS
The Chiesi Group has undergone B Corp re-certification and set itself new, even more demanding operational goals until 2025
The Chiesi Group monitors the implementation of measures for a healthier and more sustainable future
Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH
RARE IS NOT SO RARE: #WEWEARSTRIPES CAMPAIGN 2022 LAUNCHED TO MARK RARE DISEASE DAY
Helping the World to Breathe - Chiesi Group among the protagonist of the ATS docuseries
Chiesi accelerates path toward full sustainability despite Covid-19 pandemic
Chiesi Group calls for #ActionOverWords in the fight against climate change
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
Chiesi Group receives the European marketing authorisation for Trimbow® (beclometasone dipropionate, formoterol fumarate, glycopyrronium) an extrafine formulation fixed triple combination therapy for the treatment of asthma
Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID- 19 pandemic
Chiesi Group Announces Establishment of New Global Rare Diseases Division